Understanding Tysabri and Progressive Multifocal Leukoencephalopathy (PML) Risk in New Jersey

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection, linked to the JC virus, requires careful monitoring. Building on decades of medical research into biologic therapies, this page provides clear facts about PML symptoms, risk factors, and current FDA recommendations for patients in New Jersey.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn disease. Its mechanism of action involves binding to alpha-4 integrins on the surface of lymphocytes, thereby preventing these immune cells from crossing the blood-brain barrier. While this reduces neuroinflammation in multiple sclerosis, it also impairs normal immune surveillance of the central nervous system. This immunosuppressive effect creates an environment in which the JC virus (JCV), a common and typically harmless polyomavirus, can reactivate and cause Progressive Multifocal Leukoencephalopathy (PML), a severe and often fatal demyelinating disease of the brain. The clinical presentation of PML is variable and can include progressive weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is typically confirmed by brain MRI showing characteristic demyelinating lesions and by detection of JCV DNA in the cerebrospinal fluid. As noted in a large retrospective cohort study, PML is a severe demyelinating disease caused by JC polyomavirus, affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study included 456 cases with either definite or clinico-radiological PML diagnosis observed between 1987 and 2024.

Risk Factors and Regulatory Warnings

The link between Tysabri and PML is well-established and is the subject of a boxed warning in the drug's prescribing information. The warning states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri. The mechanistic pathway linking Tysabri to PML is rooted in its pharmacological action. By blocking lymphocyte trafficking into the central nervous system, Tysabri reduces the immune system's ability to control JCV replication. In immunocompromised patients, JCV can infect oligodendrocytes, leading to lytic destruction of myelin-producing cells and resulting in the characteristic demyelinating lesions of PML. The drug's prescribing information emphasizes that PML typically only occurs in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Monitoring and Legal Considerations for Affected Patients

Given the severity of PML, the adequacy of warnings regarding Tysabri and PML is a critical concern. The prescribing information includes a boxed warning that clearly states the increased risk of PML and the need for monitoring. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that appropriate monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, cases of PML continue to occur. The timeline between exposure to Tysabri and documented harm can vary. The risk increases with longer treatment duration, particularly beyond two years. However, PML has been reported in patients with shorter exposure, especially if they have other risk factors such as anti-JCV antibodies or prior immunosuppressant use. The FDA Adverse Event Reporting System (FAERS) data show that Tysabri is associated with a wide range of adverse events, including fatigue, multiple sclerosis relapse, headache, and gait disturbance (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not listed among the most frequently reported events in this dataset, its occurrence is a known and serious risk. For patients who develop PML after Tysabri treatment, legal considerations may arise. Attorney-related considerations for affected patients include evaluating whether the warnings provided were adequate and whether the patient was properly monitored. The boxed warning and the TOUCH program are designed to mitigate risk, but questions may arise about whether these measures were effectively implemented in individual cases. Patients who suffer severe disability or death from PML may seek legal recourse to address medical costs, lost income, and pain and suffering.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a monoclonal antibody used for multiple sclerosis and Crohn disease. It works by blocking immune cells from entering the brain, which can allow the JC virus to reactivate and cause Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection. The risk is highest in patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

Symptoms of PML include progressive weakness, visual disturbances, cognitive decline, ataxia, and speech difficulties. Diagnosis is confirmed by brain MRI showing demyelinating lesions and detection of JCV DNA in cerebrospinal fluid (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options are available for patients who developed PML from Tysabri?

Patients who developed PML after Tysabri treatment may have legal recourse if warnings were inadequate or monitoring was insufficient. An attorney can evaluate whether the boxed warning and TOUCH program were properly implemented, and seek compensation for medical costs, lost income, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.